4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome

Journal of Assisted Reproduction and Genetics

Volumn 24, Issue 9, 2007, Pages 412-418

  Karadeniz, Muammer ^a   Erdogan, Mehmet ^a   Berdeli, Afig ^a   Saygili, Fusun ^a   Yilmaz, Candeger ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

PAI 1 gene; Polycystic ovary syndrome; TPA gene

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ALU SEQUENCE; ARTICLE; BLOOD CLOTTING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROMOTER REGION; TURKEY (REPUBLIC);

ADULT; ALU ELEMENTS; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; TISSUE PLASMINOGEN ACTIVATOR; TURKEY;

EID: 34848902884     PISSN: 10580468     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10815-007-9160-7     Document Type: Article

References (44)

1. Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 2004;191(3):713-7.
2. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003;24:302-12.
3. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;83:1143-50.
4. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995;98:27S-32S.
5. Chambers JC, Kooner JS. Homocysteine: a novel risk factor for coronary heart disease in UK Indian Asians. Heart 2001;86 2:121-2.
6. Kannel WB, D'Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672-6.
7. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001;86:4666-73.
8. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-5.
9. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996;45:623-9.
10. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999;82:1121-6.
11. Grancha S, Estelles A, Torno G, Falco C, Gilabert J, Espana F, et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999;81:516-21.
12. Degen SJ, Rajput B, Reich E. The human tissue plasminogen activator gene. J Biol Chem 1986;25;261(15):6972-85.
13. van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator (tPA) gene does not affect basal endothelial TPA synthesis. Thromb Haemost 1995;74:1202.
14. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19 1:41-7.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
16. Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, et al. Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 2002;74:1147-52.
17. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
18. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004;150:793-8.
19. Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK, et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000;49:845-52.
20. Glueck CJ, Awadalla SG, Phillips H, Cameron D, Wang P, Fontaine RN. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. Fertil Steril 2000;74:394-7.
21. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48:1589-95.
22. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75:46-52.
23. Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004;10:323-34.
24. Glueck CJ, Wang P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism 2003;52:1627-32.
25. Dahlgren E, Janson PO, Johansson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994;61:455-60.
26. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998;79:975-9.
27. Avellone G, Di Garbo V, Cordova R, Rotolo G, Abruzzese G, Raneli G, et al. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Resolution 1994;25:85-92.
28. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995;44:37-42.
29. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin levels and relative body weight in normal and obese subjects. Metabolism 1986;35:250-3.
30. Ladenvall P, Nilsson S, Jood K, Rosengren A, Blomstrand C, Jern C. Genetic variation at the human tissue-type plasminogen activator (TPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet 2003;11:603-10.
31. Sartori MT, Saggiorato G, Spiezia L, Varvarikis C, Carraro G, Patrassi GM, et al. Influence of the Alu-repeat I/D polymorphism in TPA gene intron 8 on the stimulated TPA release after venous occlusion. Clin Appl Thromb Hemost 2003;9:63-9.
32. McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia 1996;39:1512-18.
33. Matsubara Y, Murata M, Isshiki I, Watanabe R, Zama T, Watanabe G, et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int J Hematol 1999;69:43-7.
34. Hooper WC, Lally C, Austin H, Renshaw M, Dilley A, Wenger NK, et al. The role of the TPA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 2000;99:223-30.
35. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
36. Carter AM, Catto AJ, Grant PJ. Determinants of TPA antigen and associations with coronary artery disease and acute cerebrovascular disease. Thromb Haemost 1998;80:632-6.
37. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, deJong PTVM, et al. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam study. Circulation 1997;95:2623-7.
38. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality on long term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation 1993;88:2030-4.
39. Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 2006;152 6:1109-15.
40. Ridker PM, Baker MT, Hennekens CH, Stampfer MJ, Vaughn DE. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (TPA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol 1997;17:1687-90.
41. Steeds R, Adams M, Smith P, Channer K, Samani NJ. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects. Thromb Haemost 1998;79:980-4.
42. Ernst E, Resch L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
43. Stone MC, Thorp JM. Plasma fibrinogen-a major coronary risk factor. J R Coll Gen Pract 1985;35:565-9.
44. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997;54(Suppl 3):32-40.